Clinical Trial Update: A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH) [Phase 4]

View source ↗

Summary

A Phase 4 safety and efficacy study evaluating bimatoprost 0.01% in primary open-angle glaucoma or ocular hypertension; results were posted on 2014-01-28.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• Lumigan (bimatoprost)

Snippet

Sponsor: Allergan | Conditions: Glaucoma, Open-Angle, Ocular Hypertension | Phase 4 | Status: COMPLETED | Results posted: 2014-01-28